America’s ascendance as the world’s leader in life-sciences innovation has been the result of thoughtful, intentional public policies, including robust funding for the National Institutes of Health. The benefits of that funding have been significantly amplified by the 1980 Bayh-Dole Act, which gives universities and research institutions ownership of the intellectual property (IP) stemming from discoveries made in part from federally funded scientific research. Hailed as “possibly the most inspired piece of legislation to be enacted in America over the past half-century,” the Bayh-Dole Act plays a critical role in spurring the commercialization of basic life-sciences research from U.S. universities into life-saving medicines. Yet, in an attempt to control drug prices, some have called for the federal government to inappropriately exercise controversial provisions in the law that allow it to “march in” and grant licenses for patents that resulted from publicly funded R&D.
Please join ITIF for a discussion of the Bayh-Dole Act’s key role in catalyzing American leadership in life sciences and why implementing march-in rights would harm research universities and limit further innovation.
Lunch will be available during the event.